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Objective: Apparent mineralocorticoid excess (AME) is an autosomal recessive disorder
caused by the 11b-hydroxysteroid dehydrogenase type 2 (11b-HSD2) enzyme deficiency,
traditionally assessed by measuring either the urinary cortisol metabolites ratio
(tetrahydrocortisol+allotetrahydrocortisol/tetrahydrocortisone, THF+5aTHF/THE) or the
urinary cortisol/cortisone (F/E) ratio. Exosomal mRNA is an emerging diagnostic tool
due to its stability in body fluids and its biological regulatory function. It is unknown
whether urinary exosomal HSD11B2mRNA is related to steroid ratio or the HSD11B2 662
C>G genotype (corresponding to a 221 A>G substitution) in patients with AME and
essential hypertension (EH).
Aim of the Study: To detect and quantify HSD11B2 mRNA from urinary exosomes in
samples from family members affected by AME and EH, and to evaluate the relationship
between exosomal HSD11B2 mRNA, steroid ratio, 662C>G genotype, and hypertension.
Methods: In this observational case–control study, urinary steroid ratios and biochemical
parameters were measured. Urinary exosomes were extracted from urine and exosomal
HSD11B2mRNAwas quantified by Droplet Digital PCR (ddPCR). B2M (b-2 microglobulin)
gene was selected as the reference housekeeping gene.
Results: Among family members affected by AME, exosomal urinary HSD11B2 mRNA
expression was strictly related to genotypes. The two homozygous mutant probands
showed the highest HSD11B2 mRNA levels (median 169, range 118–220 copies/µl) that
progressively decreased in 221 AG heterozygous with hypertension (108, range 92–124
copies/µl), 221 AG heterozygous normotensives (23.35, range 8–38.7 copies/µl), and
wild-type 221 AA subjects (5.5, range 4.5–14 copies/µl). Heterozygous hypertensive
subjects had more HSD11B2 mRNA than heterozygous normotensive subjects. The F/E
urinary ratio correlated with HSD11B2 mRNA copy number (p < 0.05); HSD11B2 mRNA
strongly decreased while THF+5aTHF/THE increased in the two probands after therapy.n.org August 2021 | Volume 12 | Article 6819741
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Frontiers in Endocrinology | www.frontiersiIn the AME family, HSD11B2 copy number correlated with both F/E and THF+5aTHF/THE
ratios, whereas in EH patients, a high F/E ratio reflected a reduced HSD11B2 mRNA
expression.
Conclusions: HSD11B2 mRNA is detectable and quantifiable in urinary exosomes;
its expression varies according to the 662 C>G genotype with the highest levels in
homozygous mutant subjects. The HSD11B2 mRNA overexpression in AME could be
due to a compensatory mechanism of the enzyme impairment. Exosomal mRNA is a
useful tool to investigate HSD11B2 dysregulation in hypertension.Keywords: apparent mineralocorticoid excess, 11b-hydroxysteroid dehydrogenase type 2, urinary cortisol
metabolites ratio, urinary exosomal mRNA, Droplet Digital PCR, HSD11B2, essential hypertensionINTRODUCTION
Apparent mineralocorticoid excess (AME) is a rare autosomal
recessive disorder caused by the 11b-hydroxysteroid dehydrogenase
type 2 (11b-HSD2) enzyme deficiency that consequently leads to
an activation of the mineralocorticoid receptor (MR) not
mediated by aldosterone (1). The MR is characterized by
similar affinity for both aldosterone and cortisol, but in spite of
the higher plasma concentration of cortisol as compared to that
of aldosterone (about 100-fold), specific MR activation by
aldosterone is physiologically guaranteed because of the
specific 11b-HSD2 enzymatic activity. The enzyme, in fact,
converts the active steroids cortisol and corticosterone
respectively into their inactive metabolites, i.e., cortisone and
11-dehydrocorticosterone, thus allowing a functional selectivity
of aldosterone to activate MR and regulate the epithelial sodium
transport (2, 3). An impaired 11b-HSD2 function leads to an
accumulation of active steroid forms in the renal distal tubular
cells, with subsequent MR activation and sodium retention with
the development of a clinical syndrome characterized by sodium
retention, hypokalemia, salt-dependent hypertension, low
renin, and suppressed aldosterone concentrations (1, 4–7).
The activity of the 11b-HSD2 enzyme can be estimated
either by measuring the urinary cortisol metabolites ratio
(tetrahydrocortisol+allotetrahydrocortisol/tetrahydrocortisone,
THF+5aTHF/THE) or by measurement of serum or urinary free
cortisol/cortisone ratio (F/E). An increase in urinary (THF
+5aTHF)/THE ratio or urinary F/E indicates a decreased
11b-HSD2 activity.
AME is a rare disease per se although it was hypothesized that
a mild reduction of 11b-HSD2 activity can have a role also in low
renin essential hypertension (EH). Milder forms of AME,
recently named as “non-classic” AME, are at higher prevalence
than classic AME, have a different phenotype and genotype, and
are mainly related only to a partial enzymatic deficiency (8–10).
Urinary extracellular vesicles and especially urinary exosomes
are secreted by renal tubular epithelial cells and carry nucleic
acids, proteins, and lipids; they can be easily detected in urine
and provide diagnostic and pathophysiological information
without an invasive tissue biopsy (11–13).
Exosomes have a size of 40–100 nm, are secreted by all cell
types, and are composed of a lipid bilayer with membranen.org 2receptors and nucleic acids inside. They are involved in
extracellular trafficking, differentiation, and survival, and could
provide information about transcription in cells of urogenital
tissue. HSD11B2 mRNA is expected to be present in urinary
exosomes, considering the tubular localization of the enzyme;
however, its presence in exosomes has not been documented so
far. Some authors hypothesized the usefulness of detecting
HSD11B2 or even other exosomal mRNAs for the study of the
pathophysiological mechanisms of hypertensive diseases and in
particular for the diagnosis of mineralocorticoid hypertension
(14). Urinary exosomes are considered extremely valuable for
diagnostic purposes as they are considered as kidney liquid
biopsies (15) because urinary EVs (uEVs) are mainly derived
from renal cells while circulating serum EVs, under physiological
conditions, cannot cross the nephron barrier (12, 16). The
investigation of the urinary exosomal expression of HSD11B2
can therefore open up novel perspectives in the complex
diagnostic and prognostic processes in non-classic forms of EH
and especially in AME. In this context, our study was aimed to
identify an accurate method to detect and quantify HSD11B2
mRNA from urinary exosomes in samples from family members
affected by AME (17) and in EH patients to investigate a possible
relationship between urinary exosomal HSD11B2 mRNA,
steroid ratio, HSD11B2 662 C>G genotype (corresponding to a
221 Ala>Gly substitution in the amino acid sequence), and
hypertension status.MATERIALS AND METHODS
In this observational case–control study, we compared HSD11B2
exosomal mRNA copy numbers and urinary steroid ratios
measured by two different methods, in AME family members
and hypertensive subjects.
Subjects Selection
To study HSD11B2 urinary exosomal mRNA, two groups of
subjects were enrolled: (1) hypertensive patients and (2) members
of a family affected by AME as previously described (17).
Blood sample for biochemical routine parameters, 24-h urine,
and second morning urine samples were collected for each
subject. Second morning urine was obtained the same day ofAugust 2021 | Volume 12 | Article 681974
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given to patients who provided the second morning void directly
at the outpatient clinic.
Measurement of biochemical, hormonal, and routine
laboratory tests were performed at the laboratory of the
Clinical Chemistry Institute of the Verona University Hospital.
Plasma renin and aldosterone levels were measured by
commercially available methods (Dia Sorin Diagnostics,
Vercelli, Italy), as previously described (18).
The study was approved by the Ethics Committee of our
Institution (Azienda Ospedaliera Universitaria Integrata,
Verona, Italy) and patients gave their informed written consent
after full explanation of the study.
Hypertensive Subjects
Patients were enrolled among those referring to the
Hypertension Unit of the Verona University Hospital for
resistant hypertension or for possible secondary causes of
hypertension. After the exclusion of secondary forms of
hypertension (such as nephro-parenchymal disease, primary
aldosteronism, renovascular hypertension, cathecolamine
excess, and cortisol excess) only patients for whom a diagnosis
of EH was made were included in the study. Similarly, patients
currently treated with glucocorticoids, or with a clinical history
of previous glucocorticoid treatment, were excluded. None was
taking licorice-containing sweets, or 11b-HSD2 inhibitors, such
as cancer treatment dithiocarbamates (DTCs) or fungicides such
as itraconazole, hydroxyitraconazole (OHI), and posaconazole
(19, 20).
According to the study protocol, all patients had not taken
any hypotensive drugs other than verapamil and/or alpha-
blockers over the previous 4 weeks. Plasma samples for
aldosterone and renin were obtained after at least 2 h in the
upright position and a subsequent period of 10 min in the seated
position. Blood samples for hormonal and routine parameters
were collected after overnight fasting between 8:00 and 9:00 a.m.
Biochemical parameters were determined and 24-h urine
cortisol/cortisone metabolite assay was performed on 24-h
collected urine.
Fourteen subjects with a definite diagnosis of EH (equal to the
number of the AME family members included in the study) were
selected based on the availability of biological samples for the
evaluation of HSD211B exosomal mRNA.
AME Family Members
Fourteen members of a family previously studied for a story of
AME syndrome (14) were enrolled for this study. The subjects
were subdivided according to their HSD11B2 662 C>G genotype
(homozygous, 662 GG; heterozygous, 662 AG; wild type, 662
AA) and phenotype [normotensive (N); hypertensive (H)].
Clinical and biochemical follow-up of the two probands was
also available at approximately 3 years after the diagnosis.
The two homozygous probands were not taking
antihypertensive drugs at the time of enrolment whereas the
other family members with a previous diagnosis of hypertension
were already on treatment. The two probands were followed over
time, with clinical and biochemical evaluation.Frontiers in Endocrinology | www.frontiersin.org 3F/E and THF+Allo-THF/THE
Ratio Measurement
Urinary free cortisol (F) and cortisone (E) quantification was
performed using a validated liquid chromatography tandem mass
spectrometry (LC-MS/MS) method, as extensively described
elsewhere (21). Briefly, separation and quantification of both
steroids was performed by using the MS urinary free cortisol/
cortisone kit (ISBN-BSN, Castelleone, Italy) on a Nexera X2 series
UHPLC (Shimadzu, Kyoto, Japan) coupled with a 4500 MD triple
quadrupole MS (Sciex, Milan, Italy) detector. The mean intra- and
inter-assay imprecision were between 1.7% and 11.3%
Total tetrahydro-cortisol (THF), 5a-tetrahydrocortisol (5a-
THF), and tetrahydro-cortisone (THE) were quantified by gas
chromatography–mass spectrometry (GC-MS) method, as
previously described (17, 22). Instrumentation used comprised an
Agilent Technologies 7890A gas chromatograph and an Agilent
Technologies 5975C inert MSD detector (Agilent Technologies Inc.,
Santa Clara, CA, USA). The mean intra- and inter-assay
imprecision were between 3.9% and 13% for both methods.




Second morning urine samples from AME family members and
patients affected by EH were collected, processed as previously
described with minor modifications (23) and stored at −80°C.
Second morning void was chosen as good option for UV
isolation based on previous reports (24, 25). Samples were thawed
at room temperature and extensively vortexed to increase exosome
yield. Aliquots of 5 ml of urine were mixed with the same volume of
a commercially available precipitating reagent (Total Exosome
Isolation Reagent from urine; ThermoFisher Scientific, Waltham,
Massachusetts, USA) and incubated for 1 h at RT according to the
manufacturer’s instructions. Urine mixed with reagent were
centrifuged at 10,000 g and 4°C for 1 h. The obtained pellet was
used for analysis after careful removal of the supernatant. Vesicle
size was checked by electron microscop.
RNA Extraction
Total exosomal RNA was extracted by a commercial kit (PureLink
RNA Micro kit; Invitrogen, Carlsbad, California, USA). According
to themanufacturer’s instructions, RNAwas extracted, purified, and
eluted in a final volume of 15 µl and stored at −80°C.
Synthesis of cDNAs was carried out using a commercial kit
(iScript Advanced cDNA synthesis kit for RT-PCR; Biorad,
Hercules, California, USA) and a preamplification step was
included (obtained by the use of SsoAdvanced PreAmp
Supermix; Biorad, Hercules, California, USA) to improve
mRNA detection and measurement. Preamplification primer
mix included the genes HSD11B2 and b-2 microglobulin (B2M).
Reverse Transcription-Droplet Digital
Polymerase Chain Reaction (ddPCR)
Droplet Digital PCR was performed at the Genomics and
Transcriptomics Platform of “Centro Piattaforme tecnologiche”August 2021 | Volume 12 | Article 681974
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digital PCR system (Bio-Rad). Reactions and processing of the
samples were obtained following the manufacturer ’s
instructions. In brief, the mix completed with cDNA samples
were loaded with a multichannel pipette into a droplet generator
cartridge and 70 µl of oils was added to the lower wells and the
cartridge or reaction plates containing the samples was placed
into a QX200 Automatic Droplet Generator (Bio-Rad) to
produce the individual droplets. Each reaction was partitioned
into ~20,000 nanoliter-sized droplets. Procedures were
standardized and performed with high care. After the PCR was
completed, the sealed plate containing the droplets was loaded in
a QX200 droplet reader for the detection of completed PCR
reaction individual droplets. Data were analyzed with Quanta
Soft Software version 1.7.4.0917 (Bio-Rad) with the thresholds
for detection set manually based on results from negative control
wells containing water instead of RNA. During all the
preparation, and in particular for the steps of droplet
generation and droplet handling, high accuracy was required
to preserve droplet integrity. The detection of HSD11B2 RNA
was assumed valid only if the housekeeping gene B2M was
present. Optimization was evaluated by the separation between
positives and negatives. qPCR results were calculated according
to the standard curves. Mean values and standard deviations of
ddPCR and qPCR were assessed using Student’s t-test.
Reproducibility was tested with three independent samples and
intra-assay coefficients of variation (CV) calculated for
HSD11B2 and B2M mRNA were <5%. Statistical significance
was achieved with p-value < 0.05. More details on RNA
quantification are available in the Supplementary Material.
Statistical Analysis
Data analysis for comparison of clinical/biochemical data was
performed using the SPSS 24.0 for Windows (SPSS, Chicago,
Illinois, USA). Quantitative data are expressed as median values
with minimum–maximum range, while categorical variables
were expressed as percentage. Continuous variables showing a
skewed distribution were analyzed on log-transformed values.
Correlations between continuous variables were assessed by
Pearson’s test. Taking into account the very limited sample size
of the different study subgroups (e.g., AME family members with
different genotypes or EH patients analyzed according toFrontiers in Endocrinology | www.frontiersin.org 4exosomal HSD11B2 RNA copy number), all the comparisons
are shown only as descriptive and not quantitative statistics.RESULTS
Subjects enrolled in the study were characterized in terms of
hormonal and biochemical parameters. In particular, the
members of the AME family presented the features shown in
Supplementary Table S1 detailed for each family member and in
Table 1 according to genotype. Family members affected by
AME displayed the typical phenotype of the disease, with
aldosterone, renin, and K lower in 221 GG subjects than in
heterozygous 221 AG and wild-type 221 AA subjects as shown in
Supplementary Figure S1. Characteristics of EH patients are
reported in Table 2. THF+aTHF/THE and F/E ratios showed a
good correlation in the whole population. As illustrated in
Figure 1, there was a positive significant correlation between
the two parameters (r = 0.9134, p < 0.0001).
Values of THF+aTHF/THE ratio measured in the AME
family were higher in 221 GG subjects (n = 2, 7.66, range
6.41–8.91) than those in the other groups, 221 AG_H (n = 4,
2.14, range 1.74–2.54), 221 AG_N (n = 3, 1.91, range 1.6–2.43),
and 221 AA (n = 4, 0.99, range 0.29-1.8) (Figure 2A). In parallel,
the highest F/E ratio values were found in 221 GG subjects (n = 2,
3.06, range 2.75–3.37) and the lowest values were found in 221
AA subjects (n = 5, 0.16, range 0.09-0.39) (Figure 2B). The F/E
ratio values also showed a decreasing trend according to
hypertensive status, 221 AG_H (n = 4, 0.70, range 0.42–0.97),
221 AG_N (n = 2, 0.47, range 0.25–0.49) (Figure 2 and Table 1).
In EH patients, mean values for THF+allo-THF/THE and F/E
were 1.59 ± 1.09 and 0.52 ± 0.35, respectively (Table 2).
Urine samples were processed for exosome extraction and
HSD11B2 exosomal mRNA was measured by ddPCR. Method
optimization and standardization was performed in order to
obtain reliable results. Samples positive for the presence of both
the housekeeping gene and the target gene were used for further
analysis. HSD11B2 mRNA was expressed as copies/µl. The
distribution of the enzyme in the different experimental groups
investigated is shown in Figure 2. In the AME family, HSD11B2
exosomal mRNA was higher in mutated subject 221 GG (169,
range 118–220 copies/µl) and progressively lower in 221TABLE 1 | Characteristics of the AME family members according to genotype*.
221 GG 221 AG 221 AA
Age 10 (7–13) 51 (25–81) 49 (20–79)
Hypertension (%) 100 57.1 20
THF+aTHF/THE ratio 7.66 (6.41–8.91) 1.91 (1.60–2.54) 0.99 (0.29–1.80)
F/E ratio 3.06 (2.75–3.37) 0.49 (0.25–0.97) 0.16 (0.09–0.39)
K (mmol/L) 2.94 (2.60–3.28) 3.97 (3.12–4.33) 3.9 (3.64–4.80)
P-Renin (pg/ml) 2.85 (2.46–3.24) 8.46 (0.84–15.96) 8.23 (6.06–40.40)
P-Aldosterone (pg/ml) <15 106 (15–134) 128 (70–185)
P-creatinine (mg/dl) 0.56 (0.44–0.68) 0.76 (0.68–0.94) 0.75 (0.71–0.99)
P-cortisol (µg/dl) 16.25 (14.80–17.70) 11.1 (10.20–18.30) 12.7 (9–22)
ACTH (pg/ml) 53.4 19 (10.70–25.50) 17.3 (0.76–51)August 2021 | Volume 1*Data are expressed as median with minimum–maximum range.2 | Article 681974
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(23.35, range 8–38.7), and wild-type 221 AA subjects (5.5, range
4.5–14). EH patients had HSD11B2 exosomal mRNA (20.9,Frontiers in Endocrinology | www.frontiersin.org 5range 5.6–79.2) lower than homozygous and heterozygous AG
H (Figure 3). HSD11B2 mRNA data were available only for nine
AME and nine EH subjects; as for the other subjects, the
housekeeping gene was undetectable.
Furthermore, the two probands of the AME family,
homozygous for the GG allele, were assessed also at 3 years
follow up. The analysis revealed that HSD11B2 exosomal mRNA
levels were greatly reduced, −86% with a decrease from 118
copies/µl to 16.6 copies/µl, and −98%, from 220 copies/µl to 5.1
copies/µl. By contrast, levels of THF+allo-THF/THE ratios were
higher than those at the time of the enrolment, from 8.91 to 12.8
and from 6.41 to 9, respectively (Figures 4A, B). Other clinical–
biochemical parameters improved from baseline, with a better
blood pressure control (in relation to antihypertensive therapy
including eplerenone, a MR receptor antagonist) andFIGURE 1 | THF+allo-THF/THE and F/E ratio correlation in the complete study population (n = 28). r = 0.9134, p < 0.0001.TABLE 2 | Biochemical and clinical features of EH patients*.
Age 49 (22–68)
Gender (M/F)% 36/64
THF+aTHF/THE ratio 1.15 (0.6–4.67)
F/E ratio 0.41 (0.18–1.63)
K (mmol/L) 3.86 (3.19–4.28)
P-Renin (pg/ml) 9.71 (1.2–33.16)
P-aldosterone (pg/ml) 185 (103–456)
P-creatinine (mg/dl) 0.82 (0.44–1.11)
P-cortisol (µg/dl) 13.95 (7–25.6)
ACTH (pg/ml) 15.96 (4.82–26.7)*Data are expressed as median with minimum-maximum range.A B
FIGURE 2 | THF+allo-THF/THE (A) and F/E (B) ratios in family affected by AME according to genotype (GG homozygous, AG heterozygous, AA wild type) and
hypertensive status (H, Hypertensive; N, Normotensive).August 2021 | Volume 12 | Article 681974
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between HSD11B2 mRNA copies and other biochemical
parameters, in particular THF+aTHF/THE and F/E ratio.
The EH population was divided into two subgroups according
to HSD11B2 mRNA copy number: the first group within the first
tertile and the second group above the first tertile value (17.12
copies/µl) (Figure 5A). Both ratios were higher in the EH group
with a lower HSD11B2 mRNA copy number (2.20, range 0.9–
4.67 vs. 1.6, range 0.68–2.2 for THF+aTHF/THE and 0.86, range
0.72–1.53 vs. 0.34, range 0.25–0.68 for F/E, respectively)
(Figure 5B). The two EH subgroups differed also in K
concentrations and age, as reported in Table 3. The main
correlations studied between HSD11B2 mRNA and
biochemical parameters are illustrated in Figure 6, where AME
subjects are represented on the left and EH patients are
represented on the right side of the figure. In the AME family,
both urinary steroid ratios correlated positively with HSD11B2
mRNA (Figures 6A, C); by contrast, the correlation was negative
in the EH population (Figures 6B, D), even if statistical
significance was reached only for F/E in the AME subjects
(Figure 6C, r = 0.7825, p-value = 0.0127). In AME, the mRNA
exosomal copies of HSD11B2 significantly inversely correlatedFrontiers in Endocrinology | www.frontiersin.org 6with aldosterone and renin (r = −0.6646, p-value = 0.0184 and
r = −0.7649, p-value = 0.0164), respectively (Figures 6E–G).
In EH patients, aldosterone levels did not show any correlation
with HSD11B2 mRNA levels (Figure 6F), while renin values
displayed a positive correlation with HSD11B2 mRNA levels (r =
0.692, p = 0.039 Figure 6H). In addition, when data were
analyzed for a possible influence of age and BMI on both
urinary steroid ratios in the whole population, no significant
correlation was observed by Pearson’s test. Furthermore, steroid
ratios were also evaluated in relation to aldosterone and renin
values either in AME or in EH subjects (Supplementary Figure
S2). THF+aTHF/THE ratio showed an inverse correlation with
aldosterone (r = −0.555, p-value = 0.0394) and an inverse but
non-significant correlation with renin (r = −0.4491, p-value =
0.1237) in the AME family (Supplementary Figure 2A) despite
the fact that, in EH, no correlation was found (Supplementary
Figures 2A, B). Similar trends were observed for F/E ratio with
renin and aldosterone levels; a significant negative correlation
was in fact found in AME (r = −0.6225, p-value = 0.0231;
r = −0.666, p-value = 0.0093, respectively) while there was no
significant correlation in EH patients (Supplementary
Figures 2C, D).A B
FIGURE 3 | HSD11B2 exosomal mRNA (copies/µl) in AME subject according to genotype (GG homozygous, AG heterozygous, AA wild type) and hypertensive
status (H, Hypertensive; N, Normotensive) (A) and in all subjects including EH (B).A B
FIGURE 4 | HSD11B2 exosomal mRNA (copies/µl) (A) and THF+allo-THF/THE ratio (B) in the two probands 221 GG mutated at enrolment and follow-up (≈3 years).August 2021 | Volume 12 | Article 681974
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To the best of our knowledge, this is the first report showing that
HSD11B2 mRNA is detectable in urinary exosomes and
correlates with the 11b-HSD2 activity estimated by urinary
steroid ratios. The results highlight, moreover, that the urinary
exosomal HSD11B2 mRNA expression varies according to the
HSD11B2 662C>G genotype in an AME family, suggesting a
potential use of it as a molecular marker of hypertensive disease,
due to an impaired 11b-HSD2 enzyme function.
The-11b-HSD2 is a crucial enzyme for the modulation of MR
activation, a key receptor at the kidney cellular level for the
regulation of sodium and water balance in arterial hypertension.
Cortisol inactivation by 11b-HSD2 mediates the ligand
selectivity of aldosterone for MR, and an impaired enzymatic
activity led to the cortisol activation of MR in AME disease.
The study of 11b-HSD2 enzyme is of interest because, even if
AME is a rare disease, with about 100 cases and overall 50
mutations described in the literature, a partial deficiency of this
enzyme was proposed also in other conditions, i.e., arterial
hypertension and renal failure. A moderate impairment of
11b-HSD2 was reported in some EH patients, and a number of
polymorphisms or genetic mutations with a mild influence on
11b-HSD2 activity were described in EH (7, 26, 27). Moreover, inFrontiers in Endocrinology | www.frontiersin.org 7relatives of AME patients, a mild form of hypertension,
indistinguishable from EH, was often described (28, 29). We
previously demonstrated that a number of EH patients and
glucocorticoid-treated patients shared a similar phenotype,
characterized by both arterial hypertension and elevated
urinary THF+aTHF/THE ratio (22). Recent research suggests
that milder forms of AME could be present in the general
population, and hypertensive patients were mislabeled as
idiopathic. This condition was previously described in
literature as AME type II (1, 7, 30), and more recently
described as “non-classic” AME, with a much higher
prevalence (7.1%) than classic AME (8, 9, 31).
In humans, the 11b-HSD iso-enzyme 11b-HSD1 (converting
the inactive cortisone into the active cortisol) is widely
distributed but it is mostly abundant in liver and adipose
tissue, whereas the 11b-HSD2 iso-enzyme (inactivating cortisol
to cortisone) is primarily expressed in MR target tissues, i.e.,
kidney, colon, and salivary gland. To study the functional role of
11b-HSD2 in the regulation of water balance, the most critical
issue is that the kidney cannot be easily available unless a renal
biopsy, i.e., an invasive procedure is made. The 11b-HSD2
enzyme activity is, therefore, usually estimated by a surrogate
marker, i.e., the urinary cortisol-to-cortisone metabolite ratios.
As a proof of this assumption in a cohort of patients undergoingA B
FIGURE 5 | Classification of EH patients in low and high HSD11B2 mRNA when below or higher than the first tertile (17.12 copies/µl), respectively. (A) THF+allo-
THF/THE ratio. (B) F/E ratio.TABLE 3 | Characteristics of EH patients divided into low and high HSD11B2 mRNA copy number*.
<17.12 ≥17.12
Age 59 (41–78) 44 (33–53)
Gender (M/F) % 33/67 50/50
THF+aTHF/THE ratio 2.2 (0.90–4.67) 1.60 (0.68–2.20)
F/E ratio 0.86 (0.72–1.53) 0.34 (0.25–0.68)
K (mmol/L) 3.40 (3.19–3.68) 4.01 (3.35–4.26)
P-Renin (pg/ml) 7.04 (1.20–7.60) 10.3 (5.28–33.16)
P-Aldosterone (pg/ml) 190 (171–283) 261 (103–456)
P-creatinine (mg/dl) 0.86 (0.59–1.11) 0.81 (0.44–0.99)
P-cortisol (µg/dl) 13.25 (11.7–15.60) 14 (7–25.6)
ACTH (pg/ml) 19.86 (14.7–26.7) 13.65 (4.82–24)August 2021 | Volume 1*Data are expressed as median with minimum-maximum range.2 | Article 681974
De Santis et al. Urinary-Exosomal HSD11B2 mRNA in Hypertensionrenal biopsy because of suspected underlying renal disease, it was
demonstrated that renal 11b-HSD2 mRNA expression relates to
both urinary cortisol metabolite ratios (THF+aTHF/THE and F/E).
Moreover, a decreased HSD11B2 expression was observed among
the patients with worse renal function (32). In different patients,
such as AME and EH, similar results have never been obtained so
that the same relationships between cortisol metabolites ratios and
11b-HSD2 activity is far from being firmly proved. In this context,
we hypothesized that urinary extracellular vesicles and exosomes
might represent a useful tool for investigation and a possible sourceFrontiers in Endocrinology | www.frontiersin.org 8of information. Since the 11b-HSD2 enzyme is expressed in the
kidney, we hypothesized that HSD11B2 mRNA is part of the
urinary exosome cargo and therefore a possible liquid biomarker
of disease related to 11b-HSD2 enzyme dysregulation. The results
here presented confirm our hypothesis.
We demonstrated that HSD11B2 mRNA is detectable in
urinary exosomes both in patients with AME syndrome and in
patients with EH. The relationship with clinical–biochemical
parameters are different in the two conditions. In the AME





FIGURE 6 | HSD11B2 exosomal mRNA levels and steroid ratio and aldosterone and renin correlations in AME subjects (on the left) and in EH patients (on the right).
11b-HSD2 exosomal mRNA showed a positive correlation with THF+allo-THF/THE ratio in AME subjects, r = 0.6266, p-value = 0.0710 (A) and an inverse correlation
in EH patients, r = −0.07793, p-value = 0.8420 (B). Similar trend was found between 11b-HSD2 exosomal mRNA and F/E ratio in AME, r = 0.7825, p-value =
0.0127 (C) and inverse in EH, r = −0.3762, p-value = 0.3184 (D). On the contrary, an inverse and significant correlation was found between 11b-HSD2 exosomal
mRNA and aldosterone and renin in AME and a positive significance for renin in EH, r = −0.6921, p-value = 0.0388 (E) and r = −0.7649, p-value = 0.00164 (G), r =
0.692, p-value = 0.039 (H), respectively. No correlation was found in EH for 11b-HSD2 exosomal mRNA and aldosterone, r = 0.081, p-value = 0.8359 (F).August 2021 | Volume 12 | Article 681974
De Santis et al. Urinary-Exosomal HSD11B2 mRNA in Hypertensionthe 662 C>G genotype: the homozygous probands showed the
highest levels, the heterozygous subjects showed intermediate
levels, and the wild-type subjects showed the lowest levels.
Among heterozygous carriers, hypertensive subjects had higher
HSD11B2 exosomal mRNA than normotensives. These data
suggest the following: (i) higher expression of the gene when
the enzymatic activity is mostly reduced, at least as estimated by
urinary steroid ratios (urinary THF/THE and THF+5aTHF/
THE ratios); (ii) 11b-HSD2 mRNA is inversely related to the
renin and aldosterone concentrations, mirroring a pronounced
inhibition of the renin–aldosterone axis. The first point may be
explained by an increased rate of transcription of the mutated
gene as a feedback mechanism to compensate for the reduced
enzymatic activity. However, this effect could be specific for the
662 C>G variant, while other mutations at different points of the
gene sequence could have inhibitory consequences on
the transcription process with reduced or absent mRNA.
The mechanisms previously investigated of the modulation of
11b-HSD2 gene expression were at pre- and post-transcriptional
levels: the presence of polymorphisms, variations in
microsatellite regions (33, 34), and epigenetic modifications,
i.e., differentially expressed miRNAs (35, 36) and CpG
methylation at the HSD11B2 promoter region (17, 37–39).
DNA methylation is the main epigenetic feature in mammalian
cells, leading to a gene transcriptional regulation by transcriptional
repression when the gene promoter site is hypermethylated (40). In
a cohort of patients treated with glucocorticoid with high urinary
THF+aTHF/THE, HSD11B2 promoter methylation in peripheral
leukocytes was associated with the development of hypertension,
suggesting a possible role of a modulation of HSD11B2 gene
expression in the pathogenesis of steroid-induced hypertension
(39). In the same AME family investigated in this study, we
previously demonstrated a lower HSD11B2 promoter methylation
in the two affected probands, compared to the wild-type individuals
(17), and this result is consistent with the present finding of a great
amount of HSD11B2 exosomal mRNA measured in the
two probands.
A further indirect demonstration of the role of a gene expression
modulation of HSD11B2 related to the entity of MR activation
derives from the data of the two probands at follow-up. At baseline,
when the two patients were free from specific therapy, with a florid
disease characterized by low-renin, low-aldosterone hypokalemic
hypertension, we observed a high exosomal HSD11B2 mRNA
expression. After a long period of antihypertensive therapy
including MR antagonist (eplerenone), along with a good blood
pressure control and normalization of renin and kalemia, we
observed a clear reduction in exosomal HSD11B2 mRNA. If
HSD11B2 gene expression at baseline was increased in order to
compensate for the excessive MR activation, a therapy-mediated
MR inhibition also reduced HSD11B2 mRNA. Interestingly, the
higher THF+aTHF/THE ratio as compared to baseline observed
after eplerenone treatment in the two boys is consistent with the
finding of a lower exosomal HSD11B2 gene expression.
The enzymatic activity of 11b-HSD2 is estimated by either
urinary THF+aTHF/THE or serum or urinary F/E ratio. It was
hypothesized that F/E may be a better marker of the activity of 11b-Frontiers in Endocrinology | www.frontiersin.org 9HSD2 isoenzyme, while THF+5aTHF/THE may represent a proxy
of global HSD11B2 activity (i.e., both 11b-HSD1 and 11b-HSD2
isoforms) (7, 41–46). Which parameter is better to assess
11b−HSD2 activity in humans remains unclear. In the population
of this study, F/E has a better correlation with exosomal HSD11B2
gene expression than the THF+aTHF/THE ratio: in the AME
family, the positive correlation between HSD11B2 exosomal
mRNA was positive for both urinary ratios, but reached the
statistical significance only for the F/E, and the negative
correlation between HSD11B2 exosomal mRNA and renin was
significant only for the F/E ratio. In the EH population, U/F better
discriminated patients according to median values of HSD11B2
mRNA than the THF+aTHF/THE ratio. However, because of the
limited sample size, we cannot definitively state that urinary F/E is
better than the THF+aTHF/THE ratio in estimating enzymatic 11b-
HSD2 activity. Further studies are needed to confirm our data.
A further strength of the study is the accuracy of the method
to quantify the urinary HSD11B2 mRNA expression since we
utilized an advanced and sensitive novel technology, namely, the
ddPCR (47) that is particularly suited for extremely low-target
quantitation from variably contaminated samples as it is based
on the partitioning of the PCR reaction into thousands of
individual reaction vessels prior to amplification and on the
acquisition of data at reaction end point. DdPCR is thus able to
give more precise and reproducible data than qPCR (48).
The present study has some limitations that need to be
acknowledged. The study sample is very limited and, therefore,
mostly descriptive, which implies that they should be interpreted
with caution. We also recognize the substantial overlap in
exosomal HSD11B2 RNA copy number between different
subgroups, including 221 GG homozygotes and hypertensive
221 AG heterozygotes, which limits the diagnostic value of such
assay. Moreover, the comparison between AME family members
and EH subjects is limited by the lack of age and sex matching.
Digital PCR has proven to be the right tool for investigating
HSD11B2 mRNA, as other approaches were not successful in
allowing the detection of such a minimal amount of material
such as the mRNA present in UVs, a limitation to get enough
mRNA to analyze all samples, even after the necessary step of
preamplification. Further studies are indeed required to confirm
these findings in a larger data set.
Despite the study limitations, our results appear biologically
plausible and could be seen as a potential proof of concept about
the role of 11bHSD2 activity in mineralocorticoid hypertension.
HSD11B2 mRNA is detectable and quantifiable in urinary
exosomes by ddPCR technology. In AME family members (662
C>G genotype), we observed an increased HSD11B2 expression
in homozygous as compared to heterozygous and wild types and
a positive correlation between exosomal mRNA and the
11bHSD2 enzyme activity as estimated by the urinary steroid
ratios, i.e., opposite to the trend observed in EH patients. The
overexpression of HSD11B2 mRNA is a possible mechanism of
compensation of the enzyme deficiency. The study of exosomal
expression is a useful tool to investigate 11b-HSD2 functional
activity in kidney through the analysis of exosomal mRNA cargo
in mineralocorticoid hypertension.August 2021 | Volume 12 | Article 681974
De Santis et al. Urinary-Exosomal HSD11B2 mRNA in HypertensionThe present study, moreover, adds to the current knowledge and
understanding that it is possible to perform a kidney tissue gene
expression analysis simply by evaluating a urine sample. It is also
possible to speculate that also other genes of interest related to
diseases with a renal involvement could be investigated and provide
novel insights for novel perspectives in clinical approaches.DATA AVAILABILITY STATEMENT
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